Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
NCT ID: NCT05447169
Last Updated: 2022-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
11625 participants
OBSERVATIONAL
2022-07-10
2030-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients
NCT03855020
Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
NCT03601390
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
NCT03544099
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
NCT01094405
"Xijiang Project" Screening Cohort for NPC
NCT06787456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High risk population of nasopharyngeal carcinoma
first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
EBV antibodies test
ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
EBV DNA test
quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EBV antibodies test
ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
EBV DNA test
quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 30-62 years old
* male
* a first-degree relative of at least one nasopharyngeal carcinoma patient
* no medical record of nasopharyngeal carcinoma
* Eastern Cooperative Oncology Group score of 0-2
* be able to comprehend, sign, and date the written informed consent document to participate in the study
Exclusion Criteria
* heavy cardiovascular, liver or kidney disease
* on systemic steroid or immunosuppressant treatment or active autoimmune disease
30 Years
62 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuzhou Red Cross Hospital
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
Hunan Cancer Hospital
OTHER
The Third Affiliated Hospital of Nanchang University
OTHER
First People's Hospital of Foshan
OTHER
Yuebei People's Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Changsha Central Hospital
OTHER
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming-Yuan Chen
professor & chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming-Yuan Chen, MD, PhD
Role: STUDY_CHAIR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYSUCC-CMY-2022-screen
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.